Service de Néphrologie Centre hospitalo-universitaire Clermont-Ferrand, Clermont-Ferrand, France.
Unité de Biostatistiques, Direction de la recherche clinique et d' innovation, Centre hospitalo-universitaire Clermont-Ferrand, Clermont-Ferrand, France.
Transpl Int. 2023 Sep 15;36:11775. doi: 10.3389/ti.2023.11775. eCollection 2023.
The impact of immunosuppressive therapy (IS) strategies after kidney transplant failure (KTF) on potential future new grafts is poorly established. We assessed the potential benefit of calcineurin inhibitor (CNI)-based IS maintenance throughout the dialysis period on the outcome of the second kidney transplant (KT). We identified 407 patients who underwent a second KT between January 2008 and December 2018 at four French KT centers. Inverse probability of treatment weighting was used to control for potential confounding. We included 205 patients with similar baseline characteristics at KTF: a total of 53 received at least CNIs on the retransplant day (G-CNI), and 152 did not receive any IS (G-STOP). On the retransplant date, G-STOP patients experienced a longer pretransplant dialysis time, were more often hyperimmunized, and underwent more expanded-criteria donor KTs than G-CNI patients. During the second KT follow-up period, rejection episodes were similar in both groups. The 10-year survival rates without death and dialysis were 98.7% and 59.5% in G-CNI and G-STOP patients, respectively. In the multivariable analysis, CNI-based IS maintenance was associated with better survival (hazard ratio: 0.08; 95% confidence interval: 0.01-0.58, = 0.01). CNI-based IS maintenance throughout the dialysis period after KTF may improve retransplantation outcomes.
肾移植失败(KTF)后免疫抑制治疗(IS)策略对潜在未来新移植物的影响尚未确定。我们评估了在透析期间维持钙调神经磷酸酶抑制剂(CNI)为基础的 IS 对第二次肾移植(KT)结局的潜在益处。我们在四个法国 KT 中心确定了 407 名在 2008 年 1 月至 2018 年 12 月期间接受第二次 KT 的患者。采用逆概率治疗加权来控制潜在的混杂因素。我们纳入了 KTF 时具有相似基线特征的 205 名患者:共有 53 名患者在再移植日接受了至少 CNI(G-CNI)治疗,152 名患者未接受任何 IS(G-STOP)治疗。在再移植日,G-STOP 患者的移植前透析时间更长,更常处于高免疫状态,且接受了更多的扩展标准供体 KT 移植。在第二次 KT 随访期间,两组排斥反应发生率相似。在 G-CNI 和 G-STOP 患者中,无死亡和透析的 10 年生存率分别为 98.7%和 59.5%。在多变量分析中,基于 CNI 的 IS 维持与更好的生存相关(风险比:0.08;95%置信区间:0.01-0.58, = 0.01)。在 KTF 后透析期间维持基于 CNI 的 IS 可能会改善再移植结局。